Werum IT Solutions Partners with Blood Centers of America

Werum IT Solutions has entered a strategic partnership with Blood Centers of America (BCA) to provide a standardized, scalable and compliant platform for the cell and gene therapy market. 

The two partners will jointly develop a seamless digital supply chain solution suite for cell and gene therapy. It will integrate manufacturing and supply chain logistics as well as the collection of autologous/allogenic cell-based raw material in the manufacture of cell and gene therapies. The cell and gene market will benefit from standardized processes, scalability of their products, full control of the chain of compliance and electronic batch recording.
 
"We are excited to partner with Werum IT Solutions, the leading MES supplier in FDA approved cell and gene therapies," says Charles Mooney, VP Bio-Development & Quality Management at the Oklahoma Blood Institute and BCA Cell Therapy Committee Chair. "To efficiently manage cell and gene therapies the market needs a comprehensive ‘vein-to-vein’ IT solution that we will create together with Werum – a novelty and important milestone in the cell and gene business."
 
"We are proud to work together with Blood Centers of America and its members on this live-saving initiative," says Dr. Andreas Fischer, Senior Head of Business Unit SafeCell at Werum IT Solutions. "We will share knowledge and resources in order to develop an end-to-end supply chain management solution of cell and gene therapies integrating manufacturing and logistics for the complex process of delivering such therapies to the patient."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com